Business

ProMIS Neurosciences PMN310 antibody shows significant cognitive benefit in The Canadian Business Journal, a mouse model of Alzheimer’s disease

Toronto, Ontario and Cambridge, Massachusetts, March 2, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutic drug targeting Accidentally folded protein Toxic oligomers and others announced today that PMN310, a leading antibody treatment candidate for Alzheimer’s disease (AD), has shown significant cognitive benefits in the widely recognized animal model of AD.

APP / L mice are a “transgenic” model of AD, where human amyloid beta oligomers cause cognitive impairment. In this model, treatment with PMN310, which selectively targets toxic oligomers of amyloid beta, used water labyrinth reading to the extent that PMN310-treated mice were indistinguishable from “non-transgenic” control mice. I saved my memory.

“This model is in close agreement with the latest understanding of Alzheimer’s disease biology that a small mass of misfolded amyloid beta (toxic oligomer) is the most pathogenic species.1“ProMIS Chief Scientific Officer Dr. Neil Cashman said. “In our opinion, studies in transgenic mouse models focused on plaque removal or monomer depletion do not represent human disease. In fact, drug candidates showing plaque reduction in animal models. Is disappointing in the clinic, and targeting amyloid monomers that function in these models has universally failed in clinical trials. “

This positive result is based on PMN310’s previous in vivo data.Published earlier2 A study on the protective activity of PMN310 in a new object recognition model in which a toxic oligomer of amyloid beta is injected into the brain of mice to cause memory impairment. In this model, co-injection of PMN310 prevented memory loss caused by toxic oligomers.

Eugene Williams, Chairman and Chief Executive Officer of ProMIS, said of today’s announcement: In parallel, we are also developing a potential subcutaneous injection of PMN310. ”

1Klein E et al. 2018. Amyloid-oligomer hypothesis: early 30 years. Journal of Alzheimer’s disease, 64, S567-S610.
2Gibbs E et al. 2019. A reasonably designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease. Scientific Reports 9: 9870. https: //doi.org/10.1038/s41598-019-46306-5

About ProMIS Neuroscience
ProMIS Neurosciences, Inc. Is an antibody therapy that selectively targets toxic misfolded oligomers involved in the development and progression of neurodegenerative diseases, especially Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease. A developmental biotechnology company focused on the discovery and development of. (PD). The company’s unique target discovery engine is based on the use of two complementary computational modeling techniques. The company applies molecular dynamics, computational discovery platforms-ProMIS ™ and aggregate coordinates-to predict new targets known as disease-specific epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario and has an office in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the PMN symbol and on the OTCQB Venture Market under the ARFXF symbol.
Visit www.promisneurosciences.com and follow us on Twitter and LinkedIn

For more information on investor public relations, please contact:
Alpine Equity Advisor
Nicholas Rigopros, President
nick@alpineequityadv.com
phone. 617 901-0785

TSX has not reviewed or is responsible for the validity or accuracy of this release. This information release contains information about specific future prospects. Because such information includes known and unknown risks, uncertainties, and other factors whose actual results, performance, or outcomes may differ materially from those described here. These statements should not be read as a guarantee of future performance or results. All forward-looking statements are based on our current beliefs, our assumptions, currently available information, and other factors. Readers should be careful not to place undue reliance on these forward-looking statements. These statements are given only as of the date of this press release. Due to the risks and uncertainties we have identified in our public securities filings, including the risks and uncertainties, actual events may differ materially from current expectations. We disclaim any intention or obligation to update or revise any forward-looking statement as a result of new information, future events, etc.

###


CBJ News Maker

ProMIS Neurosciences PMN310 antibody shows significant cognitive benefit in The Canadian Business Journal, a mouse model of Alzheimer’s disease

Source link ProMIS Neurosciences PMN310 antibody shows significant cognitive benefit in The Canadian Business Journal, a mouse model of Alzheimer’s disease

Related Articles

Back to top button